The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes

NCT00422058 on ClinicalTrials.gov · last registry update 2017-11-01

An unusually large phase 2: 564 participants, more than double the 110 typical for the stage. The sponsor logged completion for 13 September 2007. Primary outcome, as filed: Mean Change From Baseline in Body Weight at Week 20. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 564
Started: 2007-01-10
Primary completion: 2007-09-13 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Mean Change From Baseline in Body Weight at Week 20

Conditions studied

Metabolism and Nutrition Disorder · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.